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Introduction
Coronaviruses (CoVs) are viruses with a single-strand, positive-sense RNA 
genome that is approximately 30 kilobases, the largest known RNA virus 
genome. 
The genome of SARS-CoV-2, the virus responsible for the current pandemic, 
contains 82% nucleotide identity with human SARS-CoV, and 88% nucleotide 
identity with 2 bat derived SARS-like coronaviruses. Therefore the virus is 
thought to have originated in bats but transmitted to humans through some 
intermediate mammal. Human SARS-CoV-2 was sequenced against the 
Pangolin-CoV virus to determine whether the pangolin could be the intermediate 
for human SARS-CoV-2, however the bat CoV was more similar to human SARS-
CoV-2 than Pangolin-CoV. Human SARS-CoV-2 was also shown to have a 
unique peptide sequence insertion that the Pangolin-CoV does not share. 
Therefore, human SARS-CoV-2’s intermediate host is still unknown.
Introduction Continued
Diagnosis
The most common means of diagnosis for COVID-19 is real time quantitative 
polymerase chain reaction, or RT-qPCR using a nasal swab. Unfortunately, the 
sensitivity of RT-qPCR is only 50%-79%, meaning there are quite a few false 
negatives. Chest CT scans are far more sensitive for diagnosis of COVID-19, 
however they also come with shortcomings such as not being able to distinguish 
between COVID-19 or some other viral pneumonia. ELISA kits are also being 
developed by some companies and studies show that the ELISA is much more 
sensitive than RT-qPCR as well, but they are still being tested. 
Potential Treatments
Antibody Testing
A blood test for SARS-CoV-2 specific antibodies would be simple, rapid, and 
sensitive option for diagnosis of COVID-19 as well as determining if one has been 
exposed to the virus and has been able to develop the antibodies to the virus. 
IgM can be detected in the blood 3-6 days after exposure to SARS-CoV, and IgG 
can be detected after 8 days. Since SARS-CoV-2 is so similar to SARS-CoV, a 
SARS-CoV-2 IgG-IgM combined antibody test was developed under the 
assumption that SARS-CoV-2 follows the same pattern. The combined IgG-IgM 
test also allows for widespread testing for asymptomatic carriers.
Conclusion
SARS-CoV-2 is the virus responsible for the current COVID-19 pandemic. SARS-
CoV-2 is a betacoronavirus with a genome that is 82% identical to SARS-CoV. 
The virus enters T lymphocytes using its spike protein with the human 
angiotension-converting enzyme 2 as its receptor. COVID-19 is diagnosed 
through a nasal swab SARS-CoV-2 RT-PCR assay and the most common 
symptoms appear to be fever, cough, and fatigue. The median amount of time an 
individual will be contagious with the virus is 16 days. Many possible treatment 
methods have been explored including a SARS-CoV-2 specific antibody that 
could be potentially therapeutic against the virus, natural remedies, and ACE 
inhibitors. There are also IgM-IgG tests being developed that detect the 
antibodies against SARS-CoV-2 virus in the blood that could help determine 
transmission of the virus in the population as well as lead to more rapid, sensitive 
diagnosis.
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Figure 1: Current phylogenetic tree for known coronaviruses
Y. Chen, Q. Liu and D. Guo, "Emerging coronaviruses: Genome structure, replication, 
and pathogenesis," Journal of Medical Virology, vol. 92, no. 4, pp. 418-423, 2020. 
SARS-CoV-2, like SARS-CoV, enters T lymphocytes using its spike protein to 
interact with the human angiotension-converting enzyme 2 (ACE2) as its 
receptor. SARS-CoV-2 was found to have a unique peptide sequence that could 
contribute to the proteolytic cleavage of the spike protein, therefore potentially 
impacting host range and transmissibility. In previous research of SARS-CoV, it 
was found that in order for the virus to enter a host cell, an endocytic, protease-
primed cleavage event must occur. This is different from most coronavirus fusion 
proteins in that most are primed during assembly of the virus or upon release 
from the cell.
Figure 2: Docking conformation of SARS-CoV-2 spike protein (gold) 
with wild-type ACE2 (green) and its allelic variants (gray)
M. Hussain, N. Jabeen, F. Raza, S. Shabbir, B. A. A., A. Amanullah and B. Aziz, 
"Structural variations in human ACE2 may influence its binding with SARS-CoV-2 
spike protein," Journal of Medical Virology, pp. 1-7, 2020. 
Though human coronavirus infections generally involve the upper respiratory tract, 
SARS-CoV-2 patients do not tend to show prominent upper respiratory tract 
symptoms, indicating that SARS-CoV-2 target cells are in the lower respiratory 
tract. The most common symptoms of COVID-19 appear to be fever, cough, and 
fatigue, with pneumonia often developing as well. The virus has been found to be 
primarily transmitted through person-to-person contact, particularly through those 
that are infected, but asymptomatic. 
Patients with SARS-CoV-2 test positive, starting from the onset of symptoms, for a 
median of 16 days, with 26.3% testing positive after 4 weeks. This indicates that 
the viral replication in SARS-CoV-2 has a relatively long period compared to that 
of SARS-CoV. Studies also show that SARS-CoV-2 can be detected in the fecal 
matter of a recovered patient up to 10 days after the nasal test comes back 
negative, indicating the patient can stay contagious longer than originally thought.
Scanning electron microscope image of SARS-CoV-2 (yellow) 
emerging from cells (blue and pink)
https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images
One theory on a treatment for COVID-19 is angiotension-converting enzyme 
inhibitors (ACE inhibitors). ACE inhibitors block ACE2 receptors, which could 
protect against a SARS-CoV-2 infection. ACE inhibitors have both pros and cons, 
however. For example, ACE inhibitors inhibit ACE which leads to decreased 
angiotension I levels. This can cause a negative feedback loop which would 
ultimately increase ACE2 receptors, leading to more binding sites for the SARS-
CoV-2 virus. 
Some argue, however, that ACE inhibitors are beneficial. Some arguments are 
that the stimulation of negative feedback in ACE would reduce inflammation, while 
some argue that ACE inhibitors impair the ACE receptor pathway, making it harder 
for SARS-CoV-2 to bind to the receptor.
Another study showed no detectable difference in the virus progression between 
those treated with ACE inhibitors and those not treated with ACE inhibitors.
Another potential treatment that has been explored is the binding affinity of 27 
ligands occurring naturally in many cuisines to SARS-CoV-2 proteases. If any bind 
successfully, they could potentially prevent the virus from replicating. This study 
found that 15 of the 27 ligands were successful in binding to the viral proteases 
and therefore successful in hindering viral replication. More research would need 
to be done to recommend these natural ligands as a viral treatment, but the 
preliminary research was positive.
